Skip to main content

Articles

Dr. Bob Prentice

Dr. Bob Prentice passed away in Kingston on June 12 at the age of 84 after suffering complications from a heart attack.

He leaves his wife of 61 years, Gwen, their children, Gwen (Pierre), Greg, and Laura, and their grandchildren, Thomas and Laina. He is predeceased by their oldest son, Bob.

After graduating in Queen's Meds '60, Bob worked as a pathologist at the Hotel Dieu Hospital.  Dr. Prentice retired from the Department (HDH site) in 1992.

From https://thewhig.remembering.ca/obituary/bob-prentice-1082590777

 

TA Opportunities Fall 2021 & Winter 2022

Graduate Students in Pathology are invited to apply for Teaching Assistantships for several undergraduate course for the 2021-2022 academic year.

For more information:  https://www.path.queensu.ca/ta

 

Funding new frontiers in research

Six research projects at Queen’s have received funding from the New Frontiers in Research Fund’s (NFRF) 2020 Exploration competition, a program that encourages scholars to take risks, and that fosters discoveries and innovations that could have significant impacts on our world.

Tumours that arise throughout the body called neuroendocrine neoplasms (NENs) cause metastatic disease in up to 50 per cent of patients, giving those diagnosed months to years to survive. However, the molecular basis of highly variable clinical outcomes is poorly understood. Neil Renwick (Pathology and Molecular Medicine), Kathrin Tyryshkin (School of Computing) and collaborators have proposed a radical new way to investigate NENs. The researchers propose using graph neural network models, typically used in computer science, to investigate the gene networks that drive or mediate tumor aggressiveness. The understanding of these molecular social networks may improve accurate knowledge of tumour behaviour and even treatment response, improving NEN clinical outcomes.

Queen’s researchers will receive $1.5 million ($250,000 per project) from the fund to advance interdisciplinary projects with multiple partners and collaborators. Nationally, the NFRF competition will provide $14.5 million in grants to researchers across Canada, funding 117 projects.

Pharmaceuticals have become contaminants of emerging concern through increased presence in the environment through wastewater, causing great risk to ecosystems and human health. A contributor to this issue is wastewater treatment facilities that are unable to eliminate pharmaceutical ingredients and excreted drug metabolites through their operating systems. Bas Vriens (Geological Sciences and Geological Engineering) and Martin Petkovich (Biomedical and Molecular Sciences) aim to develop new technology that will act as a 'mega-liver', filtering out harmful pharmaceuticals in wastewater treatment facilities in a cost-efficient way to help ensure good health for our communities and environment.

From: https://www.queensu.ca/gazette/stories/funding-new-frontiers-research

Dr. Harriet Feilotter appointed as Director of the Ontario Molecular Pathology Research Network

Dr. Harriet Feilotter appointed as Director of the Ontario Molecular Pathology Research Network

From: https://healthsci.queensu.ca/stories/news-announcements/dr-harriet-feil…

The Faculty of Health Sciences is pleased to announce the appointment of Dr. Harriet Feilotter as Director of the Ontario Molecular Pathology Research Network (OMPRN).

Dr. Feilotter is a Professor in the Department of Pathology and Molecular Medicine at Queen’s University. She is also Director of the Molecular Genetics Laboratory at Kingston Health Sciences Centre and Chair of the Molecular Oncology Advisory Committee at Cancer Care Ontario/Ontario Health. Dr. Feilotter has worked extensively with both OMPRN and the Ontario Institute for Cancer Research (OICR) over many years, with her expertise and leadership in molecular pathology, genetics, targeted biomarkers and informatics being critical to the success of both organizations.

As Director of OMPRN, Dr. Feilotter will provide scientific leadership for a province-wide network of pathologists and laboratory scientists collaborating to carry out high-quality cancer research with a clear potential for clinical impact, as well as bringing new educational and mentoring initiatives forward in this space. Working with other OICR programs and networks she will help to foster collaboration within the Institute and across the province, with a goal of further strengthening academic pathology across Ontario.

Dr. Feilotter takes over the role as Director of OMPRN from Dr. David LeBrun, who was OMPRN’s founding director. Dr. LeBrun is a Professor in the Department of Pathology and a Principal Investigator at the Cancer Research Institute at Queen’s School of Medicine. His vision, leadership, and his expertise has been instrumental in building the Network over the past five years.

At the same time, Dr. Feilotter is being appointed to the role of Lead, Clinical Implementation at OICR. This formalizes her existing role in working with OICR leadership to provide clinical genetics expertise to support OICR’s Ontario Pathway Towards Innovation in Cancer Care (OPTICC) project, and working with stakeholders such as Cancer Care Ontario/Ontario Health, the Ontario Ministry of Health and industry partners to promote the implementation of cancer innovations within the healthcare system.